President & CEO
Joseph has served on Aerpio’s board of directors since November 2011. He founded Akebia Therapeutics, Inc. in 2007, following twenty-three years of pharmaceutical discovery and development work at P&G Pharmaceuticals. Joseph founded Aerpio as a spin out from Akebia Therapeutics, Inc in December of 2011 bringing over the Tie2 and HIF-1 activator programs. As CEO of Aerpio, Dr. Gardner successfully closed two series A financing rounds and Aerpio’s recent private placement and reverse merger, which are funding the lead Tie2 activator, AKB-9778, through Phase 2b in patients with diabetic eye disease. Dr. Gardner received his B.S. with honors in Biological Chemistry from Tulane University, earned his M.S. in Biochemistry from Utah State University and Ph.D. in Medicinal Chemistry from University of Wisconsin.